{
  "name" : "zero.sci-hub.se_6278_bcaa8703fc84c1c5604d3a89d3311eb6_sofias2017.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "The Battle of “Nano” Paclitaxel",
    "authors" : [ "Alexandros Marios Sofias", "Michael Dunne", "Gert Storm", "Christine Allen" ],
    "emails" : [ "alexandrosofias@outlook.com", "m.dunne@utoronto.ca", "g.storm@uu.nl", "cj.allen@utoronto.ca" ],
    "sections" : [ {
      "heading" : null,
      "text" : "The Battle of “Nano” Paclitaxel\nAlexandros Marios Sofias, Michael Dunne, Gert Storm, Christine Allen\nPII: S0169-409X(17)30030-3 DOI: doi:10.1016/j.addr.2017.02.003 Reference: ADR 13090\nTo appear in: Advanced Drug Delivery Reviews\nReceived date: 19 December 2016 Revised date: 21 February 2017 Accepted date: 24 February 2017\nPlease cite this article as: Alexandros Marios Sofias, Michael Dunne, Gert Storm, Christine Allen, The Battle of “Nano” Paclitaxel, Advanced Drug Delivery Reviews (2017), doi:10.1016/j.addr.2017.02.003\nThis is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T"
    }, {
      "heading" : "The Battle of “Nano” Paclitaxel",
      "text" : ""
    }, {
      "heading" : "Alexandros Marios Sofiasa,c, Michael Dunnea, Gert Stormc,d, Christine Allena,b,*",
      "text" : "a Leslie Dan Faculty of Pharmacy, Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada b Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada c Utrecht Institute of Pharmaceutical Sciences, Department of Pharmaceutics, Utrecht University, Utrecht, The Netherlands d Department of Biomaterials Science and Technology, University of Twente, Enschede, The Netherlands * Corresponding author at: Christine Allen, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario, M5S 3M2, Canada. Email addresses: alexandrosofias@outlook.com (A.M. Sofias), m.dunne@utoronto.ca (M. Dunne), g.storm@uu.nl (G. Storm), cj.allen@utoronto.ca (C. Allen)."
    }, {
      "heading" : "Abstract",
      "text" : "Paclitaxel (PTX) is one of the three most widely used chemotherapeutic agents, together with doxorubicin and cisplatin, and is first or second line treatment for several types of cancers. In 2000, Taxol, the conventional formulation of PTX, became the best selling cancer drug of all time with annual sales of 1.6 billion. In 2005, the introduction of the albuminbased formulation of PTX, known as Abraxane, ended Taxol’s monopoly of the PTX market. Abraxane’s ability to push the Taxol innovator and generic formulations aside attracted fierce competition amongst competitors worldwide to develop their own unique, new and improved formulation of PTX. At this time there are at least 18 companies focused on preclinical and/or clinical development of nano-formulations of PTX. These pharmaceutical companies are investing substantial capital to capture a share of the lucrative global PTX market. It is hoped that any formulation that dominates the market will result in tangible benefits to patients in terms of both survival and quality of life. Given all of this activity, here we address the question: Who is going to win the battle of “nano” paclitaxel?"
    }, {
      "heading" : "Keywords",
      "text" : "Nanotechnology; Nanomedicine; Paclitaxel; Taxol®; Abraxane®; Oncology"
    }, {
      "heading" : "Highlights",
      "text" : " In 2000, Taxol, the conventional formulation of paclitaxel became the best selling cancer drug of all time with annual sales of 1.6 billion\n The nanomedicine Abraxane ended Taxol’s monopoly of the paclitaxel market and is poised to reach annual sales of 1 billion this year\n Abraxane’s ability to displace Taxol encouraged small and large biotech and pharma companies to develop their own nano-formulations of this drug with several now reaching clinical development\n A comprehensive analysis of the performance of these new formulations demonstrates that they are largely clinically equivalent to Abraxane leaving significant room for design of a superior formulation\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T"
    }, {
      "heading" : "Contents",
      "text" : "1. Paclitaxel formulations: Big money deals and promising data 1.1. Taxol® vs Abraxane® 1.2. The competitors 1.3. A comparison 2. The landscape in the near future 3. Conclusion\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T"
    }, {
      "heading" : "Graphical Abstract",
      "text" : "Companies around the world are exploring the benefits of pharmaceutical nanotechnology (e.g. liposomes and micelles) for delivery of the hydrophobic anti-cancer drug paclitaxel (PTX). These PTX formulations are being evaluated for treatment of pancreatic, small cell lung, breast, ovarian, bladder, gastric, and other types of cancer.\nAC\nC\nEP TE\nD M\nAN U\nSC R\nIP T"
    }, {
      "heading" : "1. Paclitaxel formulations: Big money deals and promising data",
      "text" : "Large pharmaceutical and small biotech companies (18 in total, Figure 1) have pursued formulation development, manufacturing, acquisition of distribution rights and/or company mergers with a goal towards conquering the paclitaxel (PTX) market. Funds exchanged in business deals have ranged from a few million USD, for acquisition of distribution rights, to several billion USD, for company acquisitions. The motivation driving these deals is simple: PTX has been established worldwide as the number one chemotherapeutic agent [1], and these companies are aiming to obtain a profitable share of the PTX market. The US dominates the global oncology market (i.e. 39%) while North America, Europe, Japan and BRIC (Brazil, Russia, India, China) together comprise 88% [2]. There is tremendous potential for an efficacious formulation of PTX, that is approved in all four markets, to become a financial and clinically meaningful success.\nFigure 1. Industrial competitors in the global PTX market\nPTX is one of the most widely used chemotherapeutic agents. Many companies have developed and manufactured nanotechnology-based formulations of PTX. As well, companies have been involved in large financial deals that have provided an entry point to the PTX-market. Gray lines: formulation development and/or manufacturing; green lines: acquisition of drug formulation or distribution rights; blue lines: merger between companies; red lines: company acquisition; $: deal bellow 0.1 billion; $$: deal between 0.1-1 billion; $$$: deal between 1-10 billion; $$$$ deal over 10 billion."
    }, {
      "heading" : "1.1 Taxol® vs Abraxane®",
      "text" : "PTX has been formulated and marketed as Taxol since receiving FDA approval in 1992. By 2000, Taxol had become the best selling anti-cancer drug of all time with annual sales of $1.6 billion [3]. Since 2002, seven generic Taxol formulations have been launched by the following companies Gland Pharma, Actavis, Fresenius Kabi Oncol, Mylan Labs, Sandoz, Teva Pharms, West-Ward Pharms. This has significantly reduced the revenue resulting from sales of the innovator product [4]. The Taxol formulations rely on the use of Cremophor EL (alt. name Kolliphor EL, Macrogolglycerol ricinoleate, PEG-35 castor oil, Polyoxyl 35 hydrogenated\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\ncastor oil and Polyoxyl-35 castor oil), a synthetic, nonionic surfactant that acts as a solubilizer for PTX. Taxol is clinically approved for treatment of breast cancer (BC), metastatic breast cancer (MBC), ovarian cancer (OC), non-small cell lung cancer (NSCLC), bladder cancer, prostate cancer, melanoma, esophageal cancer, and other types of solid tumors [5]. In 2005, the introduction of Abraxane to the marketplace ended the monopoly of the innovator and generic versions of the Taxol formulation [6]. Abraxane, manufactured by Abraxis Bioscience, was approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2005 and 2008, respectively, as second-line therapy for MBC patients with resistance to an anthracycline plus taxane regimen [6,7]. Importantly, the clinical data leading to approval of Abraxane demonstrated superiority relative to Taxol in terms of a reduction in toxicity which in turn resulted in a significantly higher maximum tolerated dose (MTD) for Abraxane [8]. In 2010, Celgene Corporation acquired Abraxane/Abraxis Bioscience for $2.9 billion [9]. The outlook for Abraxane then changed significantly following successful Phase III clinical trials (NCT00540514: comparison of Abraxane and carboplatin versus Taxol and carboplatin, and NCT00844649: Abraxane and gemcitabine versus gemcitabine) [10,11] which led to the 2012 FDA approval of the drug as first-line treatment for NSCLC in combination with carboplatin, and approval by the FDA and EMA in 2013 as first-line treatment in combination with gemcitabine for metastatic pancreatic adenocarcinoma [7]. Abraxane sales have increased significantly from $387 million in 2011 [12] to $967 million in 2015 [13] and $973 million in 2016 [14] with projections as high as $1.9 billion by 2020 [15]. These figures suggest that Abraxane has the potential to surpass the incredible success of Taxol. As shown in Figure 2, Taxol’s domination of the market peaked around 2000 and decreased beyond that following expiration of its US patent in 2001 [16,17]. The current leader in the PTX-formulation market is certainly Abraxane. Nevertheless, Celgene recently provided an updated estimate of projected revenues for 2017 that indicated a decrease from an initial projection of >$1.5 billion to $1 billion, raising questions as to whether it will be feasible to reach $1.9 billion in sales by 2020 [18]. One of the major factors behind the success of Abraxane is its simplicity. Abraxane includes six or seven PTX molecules bound non-covalently [19] to an albumin molecule forming a PTX-albumin primary aggregate of 4-14 nm [20,21]. These then further aggregate to form an albumin-PTX particle of approximately 130 nm in diameter [22]. Pre-clinical studies have shown that Abraxane improves efficacy, in comparison to Taxol, due to an increase in tumor accumulation of drug [23,24]. An increase in tumor accumulation, following administration of Abraxane relative to Taxol, has not been confirmed clinically. However, clinical studies have shown that the absence of Cremophor EL reduces the toxicity of the formulation, enabling a 49% higher dose of drug to be administered without corticosteroid premedication [8,25]. Table 1 highlights many of the strengths of Abraxane including ease of administration, reduction in hypersensitivity reactions, better overall response and survival, as well as improvements in life years gained (LYG) and qualityadjusted life years gained (QALYG) [8,26–30]. With respect to the toxicity profile, even though Abraxane shows a decrease in the incidence of neutropenia, an increase in incidence of neurotoxicity has been reported when Abraxane is administered in combination with Gemcitabine for treatment of pancreatic cancer (PC) [31]. In 2015, the National Institute of Health and Care Excellence (NICE) in the UK recommended that Abraxane not be funded in this disease setting “on grounds that the cost does not justify its limited benefit” [32,33]. However, this decision was over-ruled in Wales and Scotland wherein patients with\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nmetastatic pancreatic cancer continued to be provided access to Abraxane [34,35]. In 2016, following advocacy by patient groups in England and the proposal of a patient access scheme by Celgene, NICE announced a reappraisal of Abraxane for treatment of this patient population [36].\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nFigure 2. Sales of Taxol and Abraxane\nGlobal sales (in millions of USD) for Taxol (black) and Abraxane (red) from 1992 to 2016 with projected sales for 2017 (light red). Data for Taxol sales from 2009 – 2012 and 2016 are estimated. [14,16,17]\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nTable 1: A comparison between Taxol and Abraxane for the treatment of (metastatic) breast cancer.\nAbraxane treatment results in an improvement in overall response and survival, as well as a reduction in side effects. Despite its higher treatment cost, Abraxane increases life years gained (LYG) and improves quality of life. Costs are calculated based on cost-effectiveness analysis for studies performed in China, Spain, Italy, UK and Canada and pertain to the treatment of (metastatic) breast cancer [8,26–30]. *Overall response, overall survival, and toxicity rates for Taxol and Abraxane were retrieved from studies using doses of 175 mg/m2 and 260 mg/m2, respectively [26]. **The USD values (rounded in hundreds) are fixed based on inflation between the year of the study and July 28, 2016 and the conversion rate of July 28, 2016. (LYG: Life years gained, QALYG: Quality-adjusted life years gained).\nTaxol Abraxane\nAdministration q3w q3w Infusion time (min) 120-180 20-30\nDose (mg/m 2 ) 175 260\nPremedication Yes No Overall response (%) 25.2 (±5.1)* 33.2\nOverall survival (months) 12.48 15.24 Neutropenia (%) 47.0 (± 4.6) 30 Neurotoxicity (%) 6.0 (± 2.6) 10\nHypersensitivity (%) 2 0 Cost per course ($ USD)** 10000 (±5500) 16700 (±2600) LYG from use of Abraxane 0.25 (±0.04)\nCost per LYG ($ USD)** 31300 (±19800) QALYG from use of Abraxane 0.19 (± 0.2)\nCost per QALYG ($ USD)** 35500 (±14900) Conclusion Abraxane is a cost-effective alternative to Taxol\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T"
    }, {
      "heading" : "1.2 The competitors",
      "text" : ""
    }, {
      "heading" : "At this time, the most immediate threat to Abraxane’s market leadership is Cynviloq™ (also",
      "text" : "known as Genexol-PM). Cynviloq was originally developed by Samyang Biopharmaceuticals Corporation and approved in South Korea for the treatment of several types of cancer [37] (i.e. BC, OC, NSCLC). In 2013, Sorrento Therapeutics merged with IgDraSol (transaction valued at about $28 M) [38] and obtained exclusive distribution rights for Cynviloq in North America, the European Union, Australia [39,40] and South America in 2015 [41]. In May of 2015, Cynviloq was acquired from Sorrento by NantPharma in a deal valued at $1.3 billion ($90 million upfront cash plus $1.2 billion in milestone payments) [42,43]. The increase in value of Cynviloq has largely been attributed to preliminary positive results obtained in the TRIBECA trial. A trial designed to evaluate bioequivalence (BE) between Cynviloq and Abraxane in patients with MBC or locally recurrent BC. Indeed, initial PK results from the first eight patients enrolled in the TRIBECA™ clinical trial (NCT02064829) [44] demonstrated comparable BE between the two formulations [45–47]. The study has now been completed; however, at this point the additional data obtained has not yet been disclosed. These studies may support approval through the 505(b)(2) new drug application (NDA) regulatory pathway, a hybrid between the new entities regulatory pathway (i.e. 505(b)(1) NDA) and the abbreviated new drug application (ANDA, 505(j))[47,48]. As a reminder, the 505(b)(1) commonly includes a full non-clinical and clinical data set on the safety and effectiveness of the therapeutic. An ANDA is a type of NDA that is used to demonstrate that a generic is comparable to an innovator drug product. Generally, an ANDA 505(j) does not include data to establish safety and toxicity, rather the focus is on confirmation of pharmaceutical equivalence and demonstration of bioequivalence. Thus, an ANDA is able to rely on the innovator’s data for safety and efficacy [49]. Given Sorrento’s initial indication of pursuit of the 505(b)(2) regulatory pathway and the positive preliminary BE data already in hand in BC patients, it is conceivable that Cynviloq could soon be on the market competing with Abraxane. It is worth noting that a nanomedicine has not yet been approved through the 505(b)(2) pathway and to date few oncology products have been approved via this route [48]. Further, in March of 2015, Celgene filed a Citizen’s petition that states that “Abraxane is a novel nanotechnology agent” and that “nanotechnologies possess unique and complex characteristics” [50]. In the petition they request that “the FDA establish stringent standards with respect to any ANDA relying on approval of Abraxane as a reference listed drug and any 505(b)(2) new drug application for any similar product referencing Abraxane or paclitaxel”. Further, the petition “requests that any such applicant's product including nanoparticle formulations clinically demonstrate safety and effectiveness”. To our knowledge, the FDA has not yet responded to the filed petition. Their response will have implications for all nanomedicine formulations that aim to pursue the ANDA or 505(b)(2) routes for approval of an Abraxane “equivalent”. Meanwhile, a recent Phase III clinical trial (NCT00876486) [51] conducted in South Korea demonstrated superior clinical efficacy in comparison to a conventional Cremophor-EL based PTX formulation in patients with MBC, likely, due to the higher allowed dose (i.e. 260 mg/m2 and 175 mg/m2 for Cynviloq and the conventional formulation, respectively) [52]. Moreover, Cynviloq is currently also being evaluated for treatment of OC (NCT02739529 - Phase I trial currently recruiting [53] and NCT00877253 - Phase I clinical trial completed [54]), PC (NCT02739633 - a Phase II clinical trial currently in the pre-recruiting process [55]) and bladder cancer (NCT01426126 - a completed Phase II study [56]). Cynviloq (patent US20150366806 A1) is a relatively straightforward formulation that includes PTX solubilized in block copolymer micelles of 25 nm in diameter and formed\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nfrom mPEG-b-poly(d,l-lactide) copolymer, with an average molecular weight of 1766-2000 Da wherein 50-60 wt % of the copolymer is comprised of the hydrophilic block [46,57]. The absence of albumin in this formulation is beneficial, as it does not require an albumin donor and has a reduced risk of microbial growth [22]. A final advantage favouring Cynviloq is that patients can safely be treated in the range of 300-435 mg/m2 [46,58,59] in comparison to Abraxane which has an MTD of 300 mg/m2 [60,61]. Another recent entrant into the nano-PTX arena is Paclical®, developed by Oasmia Pharmaceutical AB whose 2015 initial public offering (IPO) raised $23 million [62]. Paclical is based on the proprietary excipient XR-17, a vitamin A derivative mixture composed of N-(alltrans-retinoyl)-L-cysteic acid methyl ester sodium salt and N-(13-cis-retinoyl)-L-cysteic acid methyl ester sodium salt that is reported to form micelles of 20 - 60 nm for solubilization of hydrophobic drugs such as PTX [63]. A Phase III clinical trial in OC patients (NCT00989131) [64] demonstrated improved overall survival for Oasmia's Paclical in combination with carboplatin compared to Taxol plus carboplatin [65]. In 2015, Paclical received approval for treatment of OC in combination with carboplatin in the Russian Federation [66]. Oasmia has applied to the EMA for market authorization [67], and has received orphan drug designation from the FDA for future use in the treatment of OC [68]. Furthermore, a head-to-head clinical study comparing Paclical and Abraxane showed similar PK profiles for these formulations, suggesting the opportunity for global approval of Paclical for treatment of BC [69,70]. Of note, Oasmia is also interested in veterinary oncology with development of Paccal Vet®-CA1 as a companion animal therapeutic, conditionally approved by the FDA [71]. This is an area that is not accessible to Celgene Corporation given the inclusion of human albumin in Abraxane. China has contributed its own PTX-formulation, Lipusu®, also known as Paclitaxel Liposome for Injection, consisting of PTX solubilized in liposomes of 400 nm in diameter formed from lecithin and cholesterol in a ratio of 87:13 wt % [72]. Lipusu was originally created by LuyePharma Group, whose Hong Kong IPO in 2014 raised $764 million [73]. Further clinical trials on Lipusu were carried out by both LuyePharma Group and Nanjing Sike Pharmaceutical [74]. Lipusu is approved in China as first-line chemotherapy for OC patients, first-line therapy for NSCLC patients who are not candidates for radiotherapy or surgery, and also for BC patients following doxorubicin treatment or in combination with cisplatin following disease recurrence [75]. Currently, there are two Phase IV clinical trials that are recruiting patients: NCT02142790 [76] in MBC patients and NCT02142010 [77] for evaluation of Lipusu in combination with cisplatin as neoadjuvant therapy in patients with BC. The MTD of Lipusu has not yet been determined; however, a Phase IV study, NCT01994031 [78], is recruiting patients for this purpose. A previous Phase I study of Lipusu (NCT00606515) [79] employed a dose of 175 mg/m2, presumably to match the commonly used dose of Taxol. The only publicly available data on the pharmacokinetics of PTX administered as Lipusu is from preclinical studies [80]. PICN (Paclitaxel Injection Concentrate for Nanodispersion) is a formulation of PTX that was developed in India by Sun Pharma Advanced Research Company (SPARC) [81]. The PICN formulation is based on SPARC's Nanotecton® technology, which utilizes nanoparticles of 100-110 nm in diameter that are formed from polyvinyl-pyrrolidone, cholesteryl sulfate and caprylic acid [82]. PICN is approved in India for the treatment of MBC [83] and has demonstrated equivalent efficacy and toxicity to Abraxane in a Phase II/III study [82] in BC patients. Given the significant success in India, additional clinical trials are now planned in order to seek FDA approval [81]. PICN is currently in Phase III (NCT02597465) evaluation in\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nthe United States for the treatment of billiary tract carcinoma [84]. PICN has also shown positive tolerability results when administered in combination with carboplatin in a Phase I trial (NCT01304303) [85,86]. NanoCarrier, a pharmaceutical company focused on employing nanomedicines for cancer therapy, has a market capitalization of $500 million (4571:Tokyo Stock Exchange) and currently has eight ongoing clinical trials in the oncology field [87]. Its contribution to the battle of nano-PTX is a polymeric micelle formulation of PTX known as NK105 that has been licensed to Nippon Kayaku. The NK105 polymeric micelles, of about 85 nm in diameter, are comprised of an amphiphilic copolymer that includes PEG as the hydrophilic block and polyaspartate modified by esterification with 4-phenyl-1-butanol as the hydrophobic block [88]. The core-forming block of this copolymer was designed to create a microenvironment within the micelle core that enables a high degree of drug loading and good drug retention with the ultimate goal of creating a true carrier that retains the drug following i.v. administration. NK105 is based on NanoCarrier’s first generation technology (i.e. passive entrapment of drug in micelles). The company currently has a number of nano-formulations in clinical development that are based on their second-generation technology that includes drug covalently conjugated or chelated to the core-forming block of the micelles. NK105, based on the company’s, first generation technology prolonged the half-life of the drug to more than 10 hours, relative to about 30 minutes for Taxol, and as result the company was expecting this formulation to make a positive contribution [89]. However, it was recently announced that a Phase III clinical trial (NCT01644890) [90] evaluating NK105 for treatment of patients with MBC or recurrent BC missed its primary endpoint [89]. The company is now pursuing a Phase I study in combination with carboplatin for the treatment of solid tumors [91]. Moreover, a Phase II clinical trial of this formulation as a treatment for patients with gastric cancer showed sufficient activity and tolerability [91,92]. SB05 (formerly Endotag®-1) is a PTX formulation that is comprised of liposomes of about 200 nm in diameter that are formed from the cationic phospholipid DOTAP and neutral phospholipid DOPC in a 53:47 molar ratio [93–95]. The formulation was developed by MediGene AG [96] and sold to the Taiwanese company SynCore Biotechnology at the end of 2015 [97] in a deal that included $5.5 million in upfront cash and opportunity for future milestone payments [98]. The acquisition of Endotag-1 by Syncore was likely motivated by results emerging from Phase II clinical trials evaluating Endotag-1 for treatment of HER2-negative BC (NCT01537536) [99], TNBC (NCT00448305) [100], PC in combination with gemcitabine (NCT00377936) [101], and hepatic metastases (NCT00542048) [102]. Current plans are to enter a Phase III clinical trial for the treatment of TNBC [94]. Another liposomal PTX formulation is LEP-ETU (Liposome Entrapped Paclitaxel Easy to Use) which includes liposomes of about 150 nm in diameter that are composed of DOPC, cholesterol, and cardiolipin in a 90:5:5 molar ratio [93,103,104]. Developed by NeoPharm, LEP-ETU underwent its first clinical trials in 2004, NCT00080418 [105] and NCT00100139 [106], which revealed a high MTD of 325 mg/m2 [107] and an equivalent PK profile to that of Taxol [108]. However, despite promising preliminary data, the company's $90 million operating loss between 2005 and 2007 [109], and subsequent delisting from the NASDAQ stock exchange in 2009 [110], significantly delayed progress. In 2010, Neopharm merged with Insys Therapeutics in a deal valued at $135 million [109,111]. In 2010, Insys Therapeutics ran a Phase II clinical trial evaluating LEP-ETU for treatment of MBC, with 275 mg/m2 as the selected dose [103]. LEP-ETU has recently received orphan drug designation\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nfor the treatment of gastric cancer [112] and OC [113] from the FDA. Although not strictly reliant on nanotechnology, an oral PTX formulation is also undergoing advanced clinical development. DHP107 is being developed by Daehwa Pharmaceutical of South Korea. This formulation is composed of PTX, monoolein, tricaprylin, and Tween 80, in a ratio of 1 : 55 : 27.5 : 16.5 wt %, which are mixed together to form an emulsion following sonication [114]. Upon oral administration, it is postulated that this formulation interacts with bile acids and spontaneously forms “micelles” of about 10 μm in diameter in the intestine [115]. In 2007, oral administration of PTX in DHP107 was shown to result in a significantly improved distribution of drug to the gastro-enteric area (i.e. stomach, jejunum, ileum, colon), compared to systemic therapy with Taxol, exhibiting a 30-2000 times higher AUC0-24 in this compartment in murine studies [115]. As a result, a Phase I clinical trial on DHP107 was conducted in patients with advanced solid tumors refractory to all standard treatments with comparison to a 175mg/m2 intravenous dose of Taxol. In these patients, DHP107 was found to be relatively safe at all doses administered (i.e. up to 600mg/m2) with no reported DLTs and no grade 4 neutropenia [116]. In 2015, the Phase III DREAM (NCT01839773) clinical study [117] demonstrated equivalent progression-free survival for oral 200mg/m2 DHP107 compared to IV 175mg/m2 Taxol [118]. This study showed for the first time that a classical chemotherapeutic agent can result in equivalent efficacy, when the appropriate formulation is used following, oral and intravenous administration (for the treatment of gastric cancer). As the oral route of administration may be more appropriate for gastric cancers compared to other indications, this strategy could facilitate treatment and patient compliance in the management of gastric cancer. Daehwa Pharmaceutical received approval for DHP107 for the treatment of gastric cancer in South Korea in September of 2016 and is now planning expansion to other markets [119,120]. The oral route of administration, and the absence of a post-Taxol approved formulation of PTX for the treatment of gastric cancer could well allow DHP107 to capture a successful share of the market. Despite the significant number of PTX formulations that are approved for clinical use or are undergoing clinical development, there are a number of new formulations that are expected to quickly reach late stage pre-clinical development and enter into clinical translation [121,122]. Co-D Therapeutics has developed Triolimus, a polymeric micelle formulation that encapsulates a triple drug combination. Triolimus is comprised of PEG-b-PLA micelles of 30- 40 nm in diameter [123]. In addition to PTX, the encapsulated combination of drugs includes the mTOR inhibitor rapamycin and the Hsp90 inhibitor tanespimycin (17-AAG) which together have been shown to exert synergistic activity [121]. Triolimus was granted orphan drug designation for treatment of angiosarcoma in 2015 and is currently in late stage preclinical evaluation for treatment of BC, NSCLC and angiosarcoma [124]. With regards to the upcoming Triolimus clinical trials, it is noteworthy that a polymeric nanomedicine delivering a combination of drugs is close to entering the market. Celator Pharmaceuticals announced successful data from their Phase III clinical trial which evaluated VYXEOS™ (formerly CPX-351), a liposome formulation co-encapsulating a synergistic ratio of cytarabine and daunorubicin, for treatment of high-risk acute myeloid leukemia [125]. Celator was acquired by Jazz Pharmaceuticals in 2016 in a deal valued at $1.5 billion [126]. Another potential threat to Abraxane is the potential introduction of a generic version of this formulation. This may not seem likely to happen soon given that Celgene holds patents for Abraxane that expire in 2026 in the US and 2022 in Europe [127].\nAC C\nEP\nTE\nD M\nAN U\nSC R\nIP T\nNevertheless, in March 2016, Allergan launched a paragraph IV Abbreviated New Drug Application (ANDA) claiming that their generic Abraxane would not infringe on Celgene’s patents and/or that their patents are unenforceable [128]. As expected, Celgene indicated that they intend to vigorously defend their IP and filed a lawsuit against Allergan [129]. Given that Celgene initiated litigation this triggered the 30-month stay in the FDA generic regulatory approval process. Thus, the earliest Allergan could receive approval for a generic version would be in 2018 [130]. As mentioned previously, there also remains the issue of the Citizen’s petition filed by Celgene that put forward that safety and efficacy studies are necessary for formulations referencing Abraxane [50]. This would likely need to be addressed by the FDA prior to acting on the ANDA filed by Allergan. Allergan is the third largest generic drug manufacturer in the US and with a current market cap of $94 billion certainly has the resources for this pending legal battle [131,132]. In addition, Actavis acquired Allergan in March 2015 in a transaction valued at $70.5 billion [133], which may provide even more strength to the implementation of a generic form of Abraxane. As well in 2016, Glenmark Pharmaceuticals of India entered into a strategic agreement with the U.S. based company Particle Sciences Inc. (a Lubrizol company) for the development of a generic version of Abraxane. Glenmark Pharmaceuticals has obtained global exclusive marketing and distribution rights for this formulation and it is indicated that Glenmark intends to file an ANDA for this generic version of Abraxane in 2019 [134]. Importantly, Celgene was denied a patent on Abraxane in India in 2015 and thus a number of generic versions of the drug are under development and/or have entered the market in this country [135,136]. Table 2 summarizes key information on each of the PTX nano-formulations discussed in this review including the company that is developing the formulation, the nature and size of the nanotechnology that comprises the formulation and current stage of development.\nTable 2: Paclitaxel nano-formulations in a nutshell.\nA summary of key information on the various paclitaxel nanoformulations. *Completed Phase III study for NK105 resulted in failure of meeting endpoints.\nFormulation Company Nanotechnology Size Status\nAbraxane Celgene Albumin-based Nanoparticle\n130 nm Approved\nInternationally\nCynviloq NantPharma Polymeric Micelle 25 nm Approved in South\nKorea\nPaclical Oasmia\nPharmaceutical AB Micelle 20-60 nm\nApproved in Russian Federation\nLipusu Luye Pharma Group Liposome 400 nm Approved in China\nPICN Sun Pharma Polymeric-Lipidic\nNanoparticle 100 nm Approved in India\nNK105 NanoCarrier Polymeric Micelle 85 nm Completed Phase II*\nSB05 SynCore\nBiotechnology Liposome 200 nm Completed Phase II\nLEP-ETU Insys Therapeutics Liposome 150 nm Completed Phase II\nDHP-107 Daehwa Pharmaceutical Emulsion (oral administration) 10 μm\nApproved in South Korea\nTriolimus Co-D Therapeutics Polymeric Micelle 40 nm Preclinical Phase\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T"
    }, {
      "heading" : "1.3 A comparison",
      "text" : "The ideal PTX formulation will have a high drug to material ratio, result in limited to no systemic toxicity or hypersensitivity reactions and yield specific and high accumulation of drugs in primary solid tumors and/or metastatic lesions. Table 3 summarizes several of the key performance related properties of the various PTX formulations. Of note, as shown, Cynviloq has the highest MTD [46,58,59] and NK105 has an AUCinf that is at least 15-fold larger than that of any of the other formulations [137]. Thus, these two formulations were expected to represent the most serious threats to the current market leader, Abraxane. However, the recent outcome from a Phase III trial on NK105 has called this formulation’s potential into question. Therefore, Cynviloq is the most advanced in terms of clinical development as it received regulatory approval in South Korea in 2007 and demonstrated BE to Abraxane, in the first eight patients enrolled, in the FDA registered TRIBECA clinical trial. However, Celgene’s Citizens Petition to the FDA [50] regarding the need for stringent standards and demonstration of safety and efficacy for ANDAs or 505(b)(2) NDAs referencing Abraxane could delay and/or prevent FDA approval of Cynviloq and other nano-formulations of PTX. The FDA’s response to this petition is of important to our field. Generally it raises the question: is bioequivalence sufficient to justify approval of a nano-formulation? In the case of generic nano-formulations, which endeavor to be identical to the FDA-approved formulation in all aspects, it is reasonable to consider ANDAs and the requirement to demonstrate BE as a sufficient level of evidence for approval. Indeed, while a generic formulation of liposomal doxorubicin was originally approved on an urgent basis in 2013 in order to address market shortages of Doxil, a generic version has since been granted FDA approval as a result of an ANDA filing on behalf of Sun Pharma [138]. In addition, the FDA is currently reviewing an ANDA filed by Actavis LLC which has partnered with Merrimack on the development of a generic version of liposomal doxorubicin hydrochloride [139]. Of note, Merrimack's generic version of Doxil was part of a large pharmaceutical deal, potentially valued at up to $1.025 billion, between Merrimack and Ipsen for acquisition of Onivyde® (irinotecan liposome injection) and generic Doxil [140], demonstrating the technical level of expertise required in producing nanomedicines. In contrast, the 505(b)(2) regulatory pathway allows companies to use existing third party data, including safety and efficacy information, in partial fulfillment of FDA submission requirements, even when the composition of the drug formulations vary. While this may be a rational approach for formulations where absorption, distribution, and clearance are the main drivers of efficacy, the authors are not convinced that BE is the main determinant of efficacy for nanoformulations. Nanomedicine drug delivery vehicles can affect drug distribution not only at the whole body level, but also distribution within tissues and indeed within cells. Furthermore, following arrival within organs and cells, drug release kinetics can significantly impact efficacy. For example, SPARC (Secreted Protein Acidic and Rich in Cysteine) overexpression is correlated with treatment response to Abraxane both in PC and head and neck cancer due to albumin’s affinity for SPARC [20,141]. In the case of Cynviloq's 505(b)(2) NDA the albumin-SPARC association may not be an issue, given the similar PK behaviour between Abraxane and Cynviloq and the high affinity of free PTX for binding to blood albumin that may enhance its affinity for SPARC in a similar way. Nevertheless, in future 505(b)(2) NDA comparisons between nano-formulations the differences in composition might influence the drug's distribution in the primary tumour and metastatic lesions both at the cellular and sub-cellular levels.\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nThe nano-formulations outlined in Table 3 and currently in clinical development benefit from the absence of human serum albumin, thereby facilitating manufacture and reducing the risk of microbial growth and viral transmission relative to Abraxane. However, most of these formulations are reported to have similar PK profiles to Abraxane (i.e. Paclical, PICN) and therefore likely act more as solubilizers of PTX rather than stable drug carriers. As a result, these formulations are most likely to result in similar (and not superior) efficacy relative to Abraxane. Indeed, these companies often highlight the BE of their formulations relative to Abraxane. Thus, the success of these drugs will be contingent on the ability of the respective companies to offer lower drug prices in comparison to Abraxane, which could potentially be afforded by more straightforward manufacturing processes. In contrast to the other clinically evaluated formulations, NK105 is the only formulation that has demonstrated significantly increased PTX residence times in the blood compartment. An increased circulation lifetime can allow the nanocarrier to take advantage of the so-called enhanced permeability and retention effect thus resulting in significantly increased tumour accumulation, as shown in preclinical models, and providing the potential for future integration of an active targeting strategy. Yet, the recent Phase III data has raised questions regarding the future promise of this formulation. The major toxicities associated with PTX, neuropathy and neutropenia, were reported to some extent for all formulations [8,137,142– 144]. Yet, each formulation results in an improvement in toxicity profile in comparison to Taxol, for which Cremophor EL is known to cause hypersensitivity reactions [143].\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nTable 3. Key performance indicators of paclitaxel formulations.\nSummary of key performance indicators and the maximum tolerated dose (MTD), plasma area under the curve (AUCinf), adverse reactions and dose limiting toxicities (DLTs) for the nine advanced drug delivery formulations of PTX that have reached clinical approval and/or development. Taxol® is included for comparison. *The MTD has been described up to 435mg/m2. **According to Oasmia's press release. ***A study to define the major PK parameters is in progress. ****PK parameters are not available from SynCore Bio.\nMTD\n(mg/m2)\nCommon Dose\n(mg/m2) AUC (h*ug/ml) Adverse Reactions and DLTs Key Performance Indicators Refs.\nTaxol® 240 175 23\n(at 210 mg/m2 dose)\nNeutropenia (grade 3 & 4) Neuropathy (grade 3) Hypotension (grade 3 & 4) Hypersensitivity\nHypersensitivity reactions due to Cremophor EL Premedication with corticosteroids is required\n[8,142,143]\nAbraxane® 300 260 16.7-19.1\n(at 300 mg/m2 dose)\nNeutropenia (grade 3 and 4) Neuropathy (grade 3)\nAbsence of toxic excipient HSA donor is required Microbial growth\n[8,44,60,61,145 ]\nCynviloq™ >300* 260 11.6\n(at 300 mg/m2 dose)\nNeutropenia (grade 3 and 4) Pneumonia (grade 3 and 4)\n> MTD than Abraxane Reduced neuropathy Similar PK to Abraxane® Premedication with corticosteroids is required\n[44,46,52,58,59, 146]\nPaclical® 250 260 Similar to\nAbraxane** Neuropathy\nReadily metabolized vitamin A-based micelle carrier Similar PK to Abraxane® [69,70,144,147]\nLipusu® TBD*** 175 TBD Neutropenia (grade 3 & 4)\nLiver Toxicity (grade 3)\nPremedication with corticosteroids is recommended Limited PK data available\n[78,79,148]\nPICN 325 260, 295\n15.6 (at 260 mg/m2\ndose)\n14.2 (at 295 mg/m2\ndose)\nNeutropenia (grade 3 & 4) Neuropathy (grade 3 & 4)\n> MTD than Abraxane Similar effectiveness to Abraxane®\n[82,86,149]\nNK105 180 180 455\n(at 180 mg/m2 dose) Neutropenia (grade 4)\nGreatest AUC Potential to pursue active targeting Reduced neuropathy Low MTD\n[88,137]\nSB05 ns**** 264\n(44x6) ns ns\nVascular targeting Efficacy compared only to Taxol® Limited PK data available\n[95,100,150,15 1]\nLEP-ETU 325 175, 275 15.9\n(at 175 mg/m2 dose)\nNeutropenia (grade 3 & 4) Neuropathy Dehydration (grade 3)\n> MTD than Abraxane Bioequivalent to Taxol® [103,107,108,1 52]\nDHP107 600 200 - Neutropenia (grade 3)\nOral administration > MTD than Abraxane Reduced adverse reactions Bioequivalent to Taxol®\n[114–116,118]\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T"
    }, {
      "heading" : "2. The landscape in the near future",
      "text" : "In the near future, we may see a number of advanced nano-formulations of PTX competing with Abraxane in the global PTX market. The PTX market can be divided into geographical regions and indications and expands when we consider the recognized 50% off-label use of drugs in oncology [153]. As shown in Figure 3, many geographical regions are putting forward their own nanoformulation of PTX – yielding the question: will each formulation be strong enough to outperform the competition to such an extent that success is achieved beyond their own location? Furthermore, the various nanoformulations of PTX are being pursued for a wide range of indications, though with inevitable overlap. Table 4 summarizes the many indications for which each nano-formulation of PTX has been approved or for which clinical trials are currently underway. Given Abraxane’s ability to largely overtake the Taxol market position and the billion dollar market at play, it is no wonder that so many companies are continuing to focus their efforts in this area.\nFigure 3. Geographical landscape of approved and planned expansion of paclitaxel formulations\nAbraxane (dark red) has been approved globally. Cynviloq (dark blue) has been approved in South Korea with Sorrento targeting approval in the western, Latin American, and Australian markets (light blue). Paclical (dark orange) is approved in the Russian federation with Oasmia seeking entry into Europe and the United States (light orange). Lipusu (green) and PICN (purple) are approved in China and India, respectively, and PICN is seeking entry into the US market (light purple). DHP107 (red) is approved in South Korea and seeking approval in other markets, possibly the United States and Europe. The competition in Northern America and Europe is fierce.\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T\nTable 4. Clinical indications for paclitaxel formulations\nThe landscape of the various nano-formulations of PTX in terms of clinical approval (green), clinical development (yellow) and/or orphan drug designation (orange). *Indicates less common cancer types (i.e. angiosarcoma, liver cancer, billiary tract carcinoma, melanoma, etc.).\nFormulation\nCancer Type\nBreast Pancreatic NSCLC Ovarian Bladder Gastric Other*\nAbraxane + + + Cynviloq + + + + + Paclical + + Lipusu + + + PICN + + + + DHP107 + NK105 + + + SB05 + + + LEP-ETU + + + Triolimus + + +"
    }, {
      "heading" : "3. Conclusion",
      "text" : "Nanomedicine formulations of conventional antitumour agents endeavor to improve both the toxicity profile and therapeutic efficacy relative to the conventional drug formulation. Abraxane succeeded in both regards, allowing it to replace Taxol as the dominant PTX chemotherapeutic and thereby conquering the lucrative PTX market. Despite the higher cost of Abraxane, the life years gained and improved quality of life it affords relative to Taxol have resulted in adoption by healthcare funding agencies and healthcare insurance providers around the world. As such, Abraxane is viewed as one of the most significant nanomedicine success stories, both in terms of patient impact and financial gain. Unsurprisingly, this success has emboldened a new generation of competitors to develop their own nanomedicine formulations of PTX to compete with Abraxane for market share. These newer formulations have generally sought to enter the market by demonstrating BE to Abraxane, but in the future it is likely that they will attempt to distinguish themselves by demonstrating superior efficacy. If this cannot be achieved, improvements in toxicity and reductions in cost could also be appealing enough to patients and payers such that they might allow these new entrants to capture a substantial share of the PTX market. This is particularly true given the rapidly developing world market for PTX and the myriad of indications for which PTX therapies are likely effective, but for which Abraxane has not yet been approved. However, the increasing off-label use of Abraxane makes targeting these other indications a risky proposition. Despite the strides that each of these new formulations has taken to capture a distinct segment of the PTX market, as yet none have demonstrated clear superiority over Abraxane. Therefore, there remains an opportunity for one of these challengers to differentiate themselves or for a completely new formulation to surpass the current competitors and thus become the new dominant player in the PTX market.\nAC C\nEP TE\nD M\nAN U\nSC R\nIP T"
    }, {
      "heading" : "Acknowledgements",
      "text" : "The authors acknowledge helpful input from Professor Marc-Andre Gagnon in the School of Public Policy and Administration at Carleton University (Ottawa, Canada). CA acknowledges a Discovery grant from NSERC, Operating grant from CIHR and a Chair in Pharmaceutics and Drug Delivery from GSK. MD acknowledges scholarships from the Dean’s Fund, Center for Pharmaceutical Oncology and OGS."
    } ],
    "references" : [ {
      "title" : "Paclitaxel ranks first among world’s anti-cancer drugs",
      "author" : [ "David Yvon" ],
      "venue" : "http://www.articlesfactory.com/articles/marketing/paclitaxel-ranks-first-amongworlds-anti-cancer-drugs.html (accessed October",
      "citeRegEx" : "1",
      "shortCiteRegEx" : "1",
      "year" : 2012
    }, {
      "title" : "Hegedûs, High affinity binding of paclitaxel to human serum albumin",
      "author" : [ "K. Paál", "L.J. Müller" ],
      "venue" : "Eur. J. Biochem",
      "citeRegEx" : "19",
      "shortCiteRegEx" : "19",
      "year" : 2001
    }, {
      "title" : "Soon-Shiong, SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients",
      "author" : [ "N. Desai", "V. Trieu", "P.B. Damascelli" ],
      "venue" : "Transl. Oncol",
      "citeRegEx" : "20",
      "shortCiteRegEx" : "20",
      "year" : 2009
    }, {
      "title" : "Challenges in development of nanoparticle-based therapeutics",
      "author" : [ "N. Desai" ],
      "venue" : "AAPS J",
      "citeRegEx" : "22",
      "shortCiteRegEx" : "22",
      "year" : 2012
    }, {
      "title" : "Increased Antitumor Activity, Intratumor Paclitaxel Concentrations, and Endothelial Cell Transport of Cremophor-Free, Albumin-Bound Paclitaxel, ABI-007, Compared with Cremophor-Based Paclitaxel, Clin",
      "author" : [ "N. Desai" ],
      "venue" : "Cancer Res",
      "citeRegEx" : "24",
      "shortCiteRegEx" : "24",
      "year" : 2006
    }, {
      "title" : "Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective",
      "author" : [ "G. Dranitsaris", "B. Yu", "L. Wang", "W. Sun", "Y. Zhou", "J. King", "S. Kaura", "A. Zhang", "P. Yuan" ],
      "venue" : "J. Oncol. Pharm. Pract",
      "citeRegEx" : "25",
      "shortCiteRegEx" : "25",
      "year" : 2016
    }, {
      "title" : "Nab-paclitaxel, docetaxel, or solventbased paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective, Clin",
      "author" : [ "G. Dranitsaris", "J. King", "S. Kaura", "B. Yu", "A. Zhang" ],
      "venue" : "Outcomes Res. Volume",
      "citeRegEx" : "26",
      "shortCiteRegEx" : "26",
      "year" : 2015
    }, {
      "title" : "An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study, Clin",
      "author" : [ "C. Lazzaro", "R. Bordonaro", "F. Cognetti", "A. Fabi", "S. De Placido", "P. Marchetti", "A. Botticelli", "Pronzato", "Martelli", "G. Arpino" ],
      "venue" : "Outcomes Res. Volume",
      "citeRegEx" : "27",
      "shortCiteRegEx" : "27",
      "year" : 2013
    }, {
      "title" : "Pérez-Alcántara, Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer",
      "author" : [ "E. Alba", "E. Ciruelos", "R. López", "J.M. López-Vega", "A. Lluch", "M. Martín", "M. Muñoz", "P. Sánchez-Rovira", "M.Á. Seguí", "F.M.R. Liria" ],
      "venue" : "in Spain,",
      "citeRegEx" : "28",
      "shortCiteRegEx" : "28",
      "year" : 2013
    }, {
      "title" : "PCN96 A UK COST-UTILITY ANALYSIS OF PACLITAXEL ALBUMIN COMPARED TO SOLVENT-BASED PACLITAXEL MONOTHERAPY AND DOCETAXEL MONOTHERAPY FOR PRETREATED METASTATIC BREAST CANCER (MBC)",
      "author" : [ "E. McLeod", "A. Lloyd", "Y. Samyshkin", "F. Prunièras", "P. Canney" ],
      "venue" : "Value Heal",
      "citeRegEx" : "29",
      "shortCiteRegEx" : "29",
      "year" : 2010
    }, {
      "title" : "Economic analysis of albuminbound paclitaxel for the treatment of metastatic breast",
      "author" : [ "G. Dranitsaris", "W. Cottrell", "B. Spirovski", "S. Hopkins" ],
      "venue" : "cancer, J. Oncol. Pharm. Pract",
      "citeRegEx" : "30",
      "shortCiteRegEx" : "30",
      "year" : 2009
    }, {
      "title" : "Albumin-Bound Paclitaxel plus Gemcitabine in Pancreatic Cancer, N",
      "author" : [ "P.B. Saltz", "Leonard B", "Bach" ],
      "venue" : "Engl. J. Med",
      "citeRegEx" : "31",
      "shortCiteRegEx" : "31",
      "year" : 2014
    }, {
      "title" : "NICE turns down pancreatic cancer drug",
      "author" : [ "S. McKee" ],
      "venue" : "Abraxane,",
      "citeRegEx" : "33",
      "shortCiteRegEx" : "33",
      "year" : 2015
    }, {
      "title" : "Ellerhorst, Phase I and Pharmacokinetic Study of ABI-007, a Cremophor-free, Protein-stabilized, Nanoparticle Formulation of Paclitaxel",
      "author" : [ "N.K. Ibrahim", "N. Desai", "S. Legha", "P. Soon-Shiong", "R.L. Theriault", "E. Rivera", "B. Esmaeli", "S.E. Ring", "A. Bedikian", "J.A.G.N. Hortobagyi" ],
      "venue" : "Clin. Cancer Res",
      "citeRegEx" : "60",
      "shortCiteRegEx" : "60",
      "year" : 2002
    }, {
      "title" : "Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors",
      "author" : [ "K. Yamada", "N. Yamamoto", "Y. Yamada", "T. Mukohara", "H. Minami", "T. Tamura" ],
      "venue" : "Jpn. J. Clin. Oncol",
      "citeRegEx" : "61",
      "shortCiteRegEx" : "61",
      "year" : 2010
    }, {
      "title" : "Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts",
      "author" : [ "L. Ye", "J. He", "Z. Hu", "Q. Dong", "H. Wang", "F. Fu", "J. Tian" ],
      "venue" : "Food Chem. Toxicol",
      "citeRegEx" : "72",
      "shortCiteRegEx" : "72",
      "year" : 2013
    }, {
      "title" : "Pharmacokinetics and biodistribution study of paclitaxel liposome in Sprague-Dawley rats and Beagle dogs by liquid chromatography-tandem mass spectrometry",
      "author" : [ "X. Wang", "L. Song", "N. Li", "Z. Qiu", "S. Zhou", "C. Li", "J. Zhao", "H. Song", "X. Chen" ],
      "venue" : "Drug Res. (Stuttg)",
      "citeRegEx" : "80",
      "shortCiteRegEx" : "80",
      "year" : 2013
    }, {
      "title" : "Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study",
      "author" : [ "M.M. Jain", "S.U. Gupte", "S.G. Patil", "A.B. Pathak", "C.D. Deshmukh", "N. Bhatt", "C. Haritha", "K. Govind Babu", "S.A. Bondarde", "R. Digumarti", "J. Bajpai", "R. Kumar", "A. V Bakshi", "G.S. Bhattacharya", "P. Patil", "S. Subramanian", "A.K. Vaid", "C.J. Desai", "A. Khopade", "G. Chimote", "P.P. Bapsy", "S. Bhowmik" ],
      "venue" : "Breast Cancer Res. Treat",
      "citeRegEx" : "82",
      "shortCiteRegEx" : "82",
      "year" : 2016
    }, {
      "title" : "Design considerations for nanotherapeutics in oncology, Nanomedicine Nanotechnology",
      "author" : [ "T. Stylianopoulos", "R.K. Jain" ],
      "venue" : "Biol. Med",
      "citeRegEx" : "83",
      "shortCiteRegEx" : "83",
      "year" : 2015
    }, {
      "title" : "A pharmacokinetic and dose-escalating study of paclitaxel injection concentrate for nano-dispersion (PICN) alone and with carboplatin in patients with advanced solid tumors",
      "author" : [ "W.W. Ma" ],
      "venue" : "in: ASCO Annu. Meet.,",
      "citeRegEx" : "86",
      "shortCiteRegEx" : "86",
      "year" : 2013
    }, {
      "title" : "NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel",
      "author" : [ "T. Hamaguchi", "Y. Matsumura", "M. Suzuki", "K. Shimizu", "R. Goda", "I. Nakamura", "I. Nakatomi", "M. Yokoyama", "K. Kataoka", "T. Kakizoe" ],
      "venue" : "Br. J. Cancer",
      "citeRegEx" : "88",
      "shortCiteRegEx" : "88",
      "year" : 2005
    }, {
      "title" : "Phase II study of NK105, a paclitaxelincorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer",
      "author" : [ "K. Kato", "K. Chin", "T. Yoshikawa", "K. Yamaguchi", "Y. Tsuji", "T. Esaki", "K. Sakai", "M. Kimura", "T. Hamaguchi", "Y. Shimada", "Y. Matsumura", "R. Ikeda" ],
      "venue" : "Invest. New Drugs",
      "citeRegEx" : "92",
      "shortCiteRegEx" : "92",
      "year" : 2012
    }, {
      "title" : "Development of liposomal formulations: From concept to clinical investigations",
      "author" : [ "Y. Fan", "Q. Zhang" ],
      "venue" : "Asian J. Pharm. Sci",
      "citeRegEx" : "93",
      "shortCiteRegEx" : "93",
      "year" : 2013
    }, {
      "title" : "Development and characterization of a novel Cremophor® EL free liposome-based paclitaxel (LEP-ETU) formulation, Eur",
      "author" : [ "J.A. Zhang", "G. Anyarambhatla", "L. Ma", "S. Ugwu", "T. Xuan", "T. Sardone", "I. Ahmad" ],
      "venue" : "J. Pharm. Biopharm",
      "citeRegEx" : "104",
      "shortCiteRegEx" : "104",
      "year" : 2005
    }, {
      "title" : "Final results of a Phase I study of Liposome Entrapped Paclitaxel (LEP-ETU) in patients with advanced cancer",
      "author" : [ "N. Damjanov", "M.N. Fishman", "J.L. Steinberg", "G.J. Fetterly", "A. Haas", "A. Grahn", "C. Lauay", "J.L. Dul", "J.W. Sherman", "E.H. Rubin" ],
      "venue" : "ASCO Meet. Abstr",
      "citeRegEx" : "107",
      "shortCiteRegEx" : "107",
      "year" : 2005
    }, {
      "title" : "Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer",
      "author" : [ "M. Slingerland", "H.-J. Guchelaar", "H. Rosing" ],
      "venue" : "Clin. Ther",
      "citeRegEx" : "108",
      "shortCiteRegEx" : "108",
      "year" : 2013
    }, {
      "title" : "Development, Optimization and Absorption Mechanism of DHP107, Oral Paclitaxel Formulation for Single-Agent Anticancer Therapy, in: New Adv",
      "author" : [ "I.-H. Lee", "J. Wan", "Y. Jang", "Y. Taek", "H. Chung" ],
      "venue" : "Basic Clin. Gastroenterol., InTech,",
      "citeRegEx" : "114",
      "shortCiteRegEx" : "114",
      "year" : 2012
    }, {
      "title" : "Efficacy and tissue distribution of DHP107, an oral paclitaxel",
      "author" : [ "J.W. Hong", "I.-H. Lee", "Y.H. Kwak", "Y.T. Park", "H.C. Sung", "I.C. Kwon", "H. Chung" ],
      "venue" : "Cancer Ther",
      "citeRegEx" : "115",
      "shortCiteRegEx" : "115",
      "year" : 2007
    }, {
      "title" : "Efficacy and safety findings from DREAM: A phase III study of DHP107 (oral paclitaxel) vs IV paclitaxel in patients with gastric cancer after failure of first-line chemotherapy",
      "author" : [ "Y.-K. Kang", "M.-H. Ryu", "S.H. Park" ],
      "venue" : "ASCO Meet. Abstr",
      "citeRegEx" : "118",
      "shortCiteRegEx" : "118",
      "year" : 2016
    }, {
      "title" : "Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG",
      "author" : [ "J.R. Hasenstein", "H.-C. Shin", "K. Kasmerchak", "D. Buehler", "G.S. Kwon", "K.R. Kozak" ],
      "venue" : "Mol. Cancer Ther",
      "citeRegEx" : "121",
      "shortCiteRegEx" : "121",
      "year" : 2012
    }, {
      "title" : "Merrimack Announces Acceptance for Review of ANDA filed by Actavis for Generic Doxorubicin",
      "author" : [ "PR Newswire" ],
      "venue" : "http://www.prnewswire.com/newsreleases/merrimack-announces-acceptance-for-review-of-anda-filed-by-actavis-forgeneric-doxorubicin-hydrochloride-liposome-injection-aka-doxil-300353884.html (accessed February",
      "citeRegEx" : "139",
      "shortCiteRegEx" : "139",
      "year" : 2016
    }, {
      "title" : "SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer, Pancreas",
      "author" : [ "J. Vaz", "D. Ansari", "A. Sasor", "R. Andersson" ],
      "venue" : null,
      "citeRegEx" : "141",
      "shortCiteRegEx" : "141",
      "year" : 2015
    }, {
      "title" : "Phase I Study of Paclitaxel by Three-hour Infusion: Hypotension Just after Infusion Is One of the Major Dose-limiting Toxicities",
      "author" : [ "T. Tamura", "Y. Sasaki", "Y. Nishiwaki", "N. Saijo" ],
      "venue" : "Japanese J. Cancer Res",
      "citeRegEx" : "142",
      "shortCiteRegEx" : "142",
      "year" : 1995
    }, {
      "title" : "Suspected anaphylactic reaction to Cremophor EL",
      "author" : [ "D. Dye", "J. Watkins" ],
      "venue" : "Br. Med. J",
      "citeRegEx" : "143",
      "shortCiteRegEx" : "143",
      "year" : 1980
    }, {
      "title" : "A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer",
      "author" : [ "H.K. Ahn", "M. Jung", "S.J. Sym", "D.B. Shin", "S.M. Kang", "S.Y. Kyung", "J.-W. Park", "S.H. Jeong", "E.K. Cho" ],
      "venue" : "Cancer Chemother. Pharmacol",
      "citeRegEx" : "146",
      "shortCiteRegEx" : "146",
      "year" : 2014
    }, {
      "title" : "A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors",
      "author" : [ "Q. Zhang", "X.-E. Huang", "L.-L. Gao" ],
      "venue" : "Biomed. Pharmacother",
      "citeRegEx" : "148",
      "shortCiteRegEx" : "148",
      "year" : 2009
    }, {
      "title" : "The efficacy and safety of paclitaxel injection concentrate for nanodispersion (PICN) at two different doses versus paclitaxel albumin-stabilized nanoparticle formulation in subjects with metastatic breast cancer",
      "author" : [ "M.M. Jain" ],
      "venue" : "(MBC), in: ASCO Annu. Meet.,",
      "citeRegEx" : "149",
      "shortCiteRegEx" : "149",
      "year" : 2014
    }, {
      "title" : "Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver",
      "author" : [ "U. Fasol", "A. Frost", "M. Büchert", "J. Arends", "U. Fiedler", "D. Scharr", "J. Scheuenpflug", "K. Mross" ],
      "venue" : "metastasis., Ann. Oncol",
      "citeRegEx" : "150",
      "shortCiteRegEx" : "150",
      "year" : 2012
    }, {
      "title" : "CT4002 study group, A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)., Ann. Oncol.  AC  C  EP  TE  D  M  AN  U  SC  R  IP  T  ACCEPTED MANUSCRIPT",
      "author" : [ "A. Awada", "I.N. Bondarenko", "J. Bonneterre", "E. Nowara", "J.M. Ferrero", "A. V Bakshi", "C. Wilke", "M. Piccart" ],
      "venue" : null,
      "citeRegEx" : "151",
      "shortCiteRegEx" : "151",
      "year" : 2014
    }, {
      "title" : "Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel",
      "author" : [ "G.J. Fetterly", "T.H. Grasela", "J.W. Sherman", "J.L. Dul", "A. Grahn", "D. Lecomte", "J. Fiedler- Kelly", "N. Damjanov", "M. Fishman", "M.P. Kane", "E.H. Rubin", "A.R. Tan" ],
      "venue" : "Clin. Cancer Res",
      "citeRegEx" : "152",
      "shortCiteRegEx" : "152",
      "year" : 2008
    }, {
      "title" : "The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO)",
      "author" : [ "P.G. Casali" ],
      "venue" : "Ann. Oncol",
      "citeRegEx" : "153",
      "shortCiteRegEx" : "153",
      "year" : 2007
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "The motivation driving these deals is simple: PTX has been established worldwide as the number one chemotherapeutic agent [1], and",
      "startOffset" : 122,
      "endOffset" : 125
    }, {
      "referenceID" : 1,
      "context" : "Abraxane includes six or seven PTX molecules bound non-covalently [19] to an albumin molecule forming a PTX-albumin primary aggregate of 4-14 nm [20,21].",
      "startOffset" : 66,
      "endOffset" : 70
    }, {
      "referenceID" : 2,
      "context" : "Abraxane includes six or seven PTX molecules bound non-covalently [19] to an albumin molecule forming a PTX-albumin primary aggregate of 4-14 nm [20,21].",
      "startOffset" : 145,
      "endOffset" : 152
    }, {
      "referenceID" : 3,
      "context" : "to form an albumin-PTX particle of approximately 130 nm in diameter [22].",
      "startOffset" : 68,
      "endOffset" : 72
    }, {
      "referenceID" : 4,
      "context" : "studies have shown that Abraxane improves efficacy, in comparison to Taxol, due to an increase in tumor accumulation of drug [23,24].",
      "startOffset" : 125,
      "endOffset" : 132
    }, {
      "referenceID" : 5,
      "context" : "However, clinical studies have shown that the absence of Cremophor EL reduces the toxicity of the formulation, enabling a 49% higher dose of drug to be administered without corticosteroid premedication [8,25].",
      "startOffset" : 202,
      "endOffset" : 208
    }, {
      "referenceID" : 11,
      "context" : "With respect to the toxicity profile, even though Abraxane shows a decrease in the incidence of neutropenia, an increase in incidence of neurotoxicity has been reported when Abraxane is administered in combination with Gemcitabine for treatment of pancreatic cancer (PC) [31].",
      "startOffset" : 271,
      "endOffset" : 275
    }, {
      "referenceID" : 12,
      "context" : "this disease setting “on grounds that the cost does not justify its limited benefit” [32,33].",
      "startOffset" : 85,
      "endOffset" : 92
    }, {
      "referenceID" : 6,
      "context" : "*Overall response, overall survival, and toxicity rates for Taxol and Abraxane were retrieved from studies using doses of 175 mg/m(2) and 260 mg/m(2), respectively [26].",
      "startOffset" : 164,
      "endOffset" : 168
    }, {
      "referenceID" : 3,
      "context" : "The absence of albumin in this formulation is beneficial, as it does not require an albumin donor and has a reduced risk of microbial growth [22].",
      "startOffset" : 141,
      "endOffset" : 145
    }, {
      "referenceID" : 13,
      "context" : "A final advantage favouring Cynviloq is that patients can safely be treated in the range of 300-435 mg/m(2) [46,58,59] in comparison to Abraxane which has an MTD of 300 mg/m(2) [60,61].",
      "startOffset" : 177,
      "endOffset" : 184
    }, {
      "referenceID" : 14,
      "context" : "A final advantage favouring Cynviloq is that patients can safely be treated in the range of 300-435 mg/m(2) [46,58,59] in comparison to Abraxane which has an MTD of 300 mg/m(2) [60,61].",
      "startOffset" : 177,
      "endOffset" : 184
    }, {
      "referenceID" : 15,
      "context" : "China has contributed its own PTX-formulation, Lipusu®, also known as Paclitaxel Liposome for Injection, consisting of PTX solubilized in liposomes of 400 nm in diameter formed from lecithin and cholesterol in a ratio of 87:13 wt % [72].",
      "startOffset" : 232,
      "endOffset" : 236
    }, {
      "referenceID" : 16,
      "context" : "The only publicly available data on the pharmacokinetics of PTX administered as Lipusu is from preclinical studies [80].",
      "startOffset" : 115,
      "endOffset" : 119
    }, {
      "referenceID" : 17,
      "context" : "The PICN formulation is based on SPARC's Nanotecton® technology, which utilizes nanoparticles of 100-110 nm in diameter that are formed from polyvinyl-pyrrolidone, cholesteryl sulfate and caprylic acid [82].",
      "startOffset" : 202,
      "endOffset" : 206
    }, {
      "referenceID" : 18,
      "context" : "PICN is approved in India for the treatment of MBC [83] and has demonstrated equivalent efficacy and toxicity to Abraxane in a Phase II/III study [82] in BC patients.",
      "startOffset" : 51,
      "endOffset" : 55
    }, {
      "referenceID" : 17,
      "context" : "PICN is approved in India for the treatment of MBC [83] and has demonstrated equivalent efficacy and toxicity to Abraxane in a Phase II/III study [82] in BC patients.",
      "startOffset" : 146,
      "endOffset" : 150
    }, {
      "referenceID" : 19,
      "context" : "PICN has also shown positive tolerability results when administered in combination with carboplatin in a Phase I trial (NCT01304303) [85,86].",
      "startOffset" : 133,
      "endOffset" : 140
    }, {
      "referenceID" : 20,
      "context" : "comprised of an amphiphilic copolymer that includes PEG as the hydrophilic block and polyaspartate modified by esterification with 4-phenyl-1-butanol as the hydrophobic block [88].",
      "startOffset" : 175,
      "endOffset" : 179
    }, {
      "referenceID" : 21,
      "context" : "Moreover, a Phase II clinical trial of this formulation as a treatment for patients with gastric cancer showed sufficient activity and tolerability [91,92].",
      "startOffset" : 148,
      "endOffset" : 155
    }, {
      "referenceID" : 22,
      "context" : "Another liposomal PTX formulation is LEP-ETU (Liposome Entrapped Paclitaxel Easy to Use) which includes liposomes of about 150 nm in diameter that are composed of DOPC, cholesterol, and cardiolipin in a 90:5:5 molar ratio [93,103,104].",
      "startOffset" : 222,
      "endOffset" : 234
    }, {
      "referenceID" : 23,
      "context" : "Another liposomal PTX formulation is LEP-ETU (Liposome Entrapped Paclitaxel Easy to Use) which includes liposomes of about 150 nm in diameter that are composed of DOPC, cholesterol, and cardiolipin in a 90:5:5 molar ratio [93,103,104].",
      "startOffset" : 222,
      "endOffset" : 234
    }, {
      "referenceID" : 24,
      "context" : "Developed by NeoPharm, LEP-ETU underwent its first clinical trials in 2004, NCT00080418 [105] and NCT00100139 [106], which revealed a high MTD of 325 mg/m(2) [107] and an equivalent PK profile to that of Taxol [108].",
      "startOffset" : 158,
      "endOffset" : 163
    }, {
      "referenceID" : 25,
      "context" : "Developed by NeoPharm, LEP-ETU underwent its first clinical trials in 2004, NCT00080418 [105] and NCT00100139 [106], which revealed a high MTD of 325 mg/m(2) [107] and an equivalent PK profile to that of Taxol [108].",
      "startOffset" : 210,
      "endOffset" : 215
    }, {
      "referenceID" : 26,
      "context" : "5 wt %, which are mixed together to form an emulsion following sonication [114].",
      "startOffset" : 74,
      "endOffset" : 79
    }, {
      "referenceID" : 27,
      "context" : "Upon oral administration, it is postulated that this formulation interacts with bile acids and spontaneously forms “micelles” of about 10 μm in diameter in the intestine [115].",
      "startOffset" : 170,
      "endOffset" : 175
    }, {
      "referenceID" : 27,
      "context" : "stomach, jejunum, ileum, colon), compared to systemic therapy with Taxol, exhibiting a 30-2000 times higher AUC0-24 in this compartment in murine studies [115].",
      "startOffset" : 154,
      "endOffset" : 159
    }, {
      "referenceID" : 28,
      "context" : "In 2015, the Phase III DREAM (NCT01839773) clinical study [117] demonstrated equivalent progression-free survival for oral 200mg/m(2) DHP107 compared to IV 175mg/m(2) Taxol [118].",
      "startOffset" : 173,
      "endOffset" : 178
    }, {
      "referenceID" : 29,
      "context" : "Despite the significant number of PTX formulations that are approved for clinical use or are undergoing clinical development, there are a number of new formulations that are expected to quickly reach late stage pre-clinical development and enter into clinical translation [121,122].",
      "startOffset" : 272,
      "endOffset" : 281
    }, {
      "referenceID" : 29,
      "context" : "In addition to PTX, the encapsulated combination of drugs includes the mTOR inhibitor rapamycin and the Hsp90 inhibitor tanespimycin (17-AAG) which together have been shown to exert synergistic activity [121].",
      "startOffset" : 203,
      "endOffset" : 208
    }, {
      "referenceID" : 30,
      "context" : "In addition, the FDA is currently reviewing an ANDA filed by Actavis LLC which has partnered with Merrimack on the development of a generic version of liposomal doxorubicin hydrochloride [139].",
      "startOffset" : 187,
      "endOffset" : 192
    }, {
      "referenceID" : 2,
      "context" : "For example, SPARC (Secreted Protein Acidic and Rich in Cysteine) overexpression is correlated with treatment response to Abraxane both in PC and head and neck cancer due to albumin’s affinity for SPARC [20,141].",
      "startOffset" : 203,
      "endOffset" : 211
    }, {
      "referenceID" : 31,
      "context" : "For example, SPARC (Secreted Protein Acidic and Rich in Cysteine) overexpression is correlated with treatment response to Abraxane both in PC and head and neck cancer due to albumin’s affinity for SPARC [20,141].",
      "startOffset" : 203,
      "endOffset" : 211
    }, {
      "referenceID" : 33,
      "context" : "Yet, each formulation results in an improvement in toxicity profile in comparison to Taxol, for which Cremophor EL is known to cause hypersensitivity reactions [143].",
      "startOffset" : 160,
      "endOffset" : 165
    }, {
      "referenceID" : 32,
      "context" : "Premedication with corticosteroids is required [8,142,143]",
      "startOffset" : 47,
      "endOffset" : 58
    }, {
      "referenceID" : 33,
      "context" : "Premedication with corticosteroids is required [8,142,143]",
      "startOffset" : 47,
      "endOffset" : 58
    }, {
      "referenceID" : 17,
      "context" : "Similar effectiveness to Abraxane® [82,86,149]",
      "startOffset" : 35,
      "endOffset" : 46
    }, {
      "referenceID" : 19,
      "context" : "Similar effectiveness to Abraxane® [82,86,149]",
      "startOffset" : 35,
      "endOffset" : 46
    }, {
      "referenceID" : 36,
      "context" : "Similar effectiveness to Abraxane® [82,86,149]",
      "startOffset" : 35,
      "endOffset" : 46
    }, {
      "referenceID" : 40,
      "context" : "The PTX market can be divided into geographical regions and indications and expands when we consider the recognized 50% off-label use of drugs in oncology [153].",
      "startOffset" : 155,
      "endOffset" : 160
    } ],
    "year" : 2017,
    "abstractText" : "Paclitaxel (PTX) is one of the three most widely used chemotherapeutic agents, together with doxorubicin and cisplatin, and is first or second line treatment for several types of cancers. In 2000, Taxol, the conventional formulation of PTX, became the best selling cancer drug of all time with annual sales of 1.6 billion. In 2005, the introduction of the albuminbased formulation of PTX, known as Abraxane, ended Taxol’s monopoly of the PTX market. Abraxane’s ability to push the Taxol innovator and generic formulations aside attracted fierce competition amongst competitors worldwide to develop their own unique, new and improved formulation of PTX. At this time there are at least 18 companies focused on preclinical and/or clinical development of nano-formulations of PTX. These pharmaceutical companies are investing substantial capital to capture a share of the lucrative global PTX market. It is hoped that any formulation that dominates the market will result in tangible benefits to patients in terms of both survival and quality of life. Given all of this activity, here we address the question: Who is going to win the battle of “nano” paclitaxel?",
    "creator" : "Elsevier"
  }
}